Efaproxiral - CAS 131179-95-8
Catalog number:
131179-95-8
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Targets:
Others
Description:
synthetic small molecule with radiosensitizing activity. Efaproxiral increases oxygen levels in hypoxic tumor tissues by binding non-covalently to the hemoglobin tetramer and decreasing hemoglobin-oxygen binding affinity. Increasing tumor oxygenation reduces tumor radioresistance. One use for efaproxiral is to increase the efficacy of certain chemotherapy drugs which have reduced efficacy against hypoxic tumours, and can thus be made more effective by increased offloading of oxygen into the tumour tissues. However, no benefit was seen for efaproxiral in phase III clinical trials.
Publictions citing BOC Sciences Products
  • >> More
Synonyms:
RSR13,Efaproxyn; NSC722758
MSDS:
Inquire
Current Developer:
Allos Therapeutics
1.The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics.
Olson JJ1, Paleologos NA, Gaspar LE, Robinson PD, Morris RE, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Patchell RA, Ryken TC, Kalkanis SN. J Neurooncol. 2010 Jan;96(1):115-42. doi: 10.1007/s11060-009-0058-3. Epub 2009 Dec 3.
QUESTION: What evidence is available regarding the emerging and investigational therapies for the treatment of metastatic brain tumors?
2.Non-cytotoxic radiosensitizers in brain radiotherapy: journey till the first decade of this millennium.
Mohindra P1, Sinha RN, Andrews RJ, Khuntia D. Curr Cancer Drug Targets. 2012 Mar;12(3):260-78.
Brain tumors, primary and metastatic, are a cause of significant mortality and morbidity. Radiotherapy (RT) forms an integral part of the treatment of brain tumors. Intrinsic relative tumor radio-resistance, normal tissue tolerance and impact on neurocognitive function, all limit the efficacy of RT. Radiosensitizers can potentially increase efficacy on tumors while maintaining normal tissue toxicity, with or without inherent cytotoxicity. This article reviews the evolution of evidence with use of non-cytotoxic radiosensitizers in brain radiotherapy and their status at the end of the first decade of this millennium. Considering, the era of development and mechanism of action, these agents are classified as first, second and third-generation non-cytotoxic radiosensitizers. The last millennium involved elaboration of first-generation compounds including halogenated pyrimidines, hypoxic cell sensitizers (e.g. imidazoles) and glycolytic inhibitors (e.
3.Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases.
Scott C1, Suh J, Stea B, Nabid A, Hackman J. Am J Clin Oncol. 2007 Dec;30(6):580-7.
OBJECTIVE: To determine whether efaproxiral, an allosteric modifier of hemoglobin, improves quality of life and quality of survival in patients with primary breast cancer and brain metastases when used as an adjunct to whole-brain radiation therapy (WBRT).
4.Reduction in hemoglobin-oxygen affinity results in the improvement of exercise capacity in mice with chronic heart failure.
Watanabe T1, Takeda T, Omiya S, Hikoso S, Yamaguchi O, Nakano Y, Higuchi Y, Nakai A, Abe Y, Aki-Jin Y, Taniike M, Mizote I, Matsumura Y, Shimizu T, Nishida K, Imai K, Hori M, Shirasawa T, Otsu K. J Am Coll Cardiol. 2008 Aug 26;52(9):779-86. doi: 10.1016/j.jacc.2008.06.003.
OBJECTIVES: This study examined whether a reduction in hemoglobin-oxygen affinity improves exercise capacity in mice with heart failure.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 4394-00-7 Niflumic Acid

Niflumic Acid
(CAS: 4394-00-7)

A selective COX-2 inhibitor; GPR35 activator; Cox-2: IC50 = 918 nM (human); Cox-1: IC50 = 1.06 µM (human); GPR35: IC50 = 1.28 µM (human)

OTX008
(CAS: 286936-40-1)

OTX008, a calixarene derivative, is a galectin-1 (Gal-1) inhibitor with potential anti-angiogenic and antineoplastic activities. In vitro, OTX008 effects in a p...

CAS 1492-02-0 Glybuzole

Glybuzole
(CAS: 1492-02-0)

Glybuzole, a benzenesulfonamide derivative, has been found to have antihyperglycemic through stimulating the release of insulin.

CAS 300586-90-7 OAC1

OAC1
(CAS: 300586-90-7)

OAC1 is a Octamer-binding transcription factor 4 (Oct4)-activating compound; enhances the iPSC reprogramming efficiency and accelerated the reprogramming proces...

CAS 35899-54-8 5'-Isobutylthio-5'-deoxyadenosine

5'-Isobutylthio-5'-deoxyadenosine
(CAS: 35899-54-8)

5'-Isobutylthio-5'-deoxyadenosine acts as a selectively spermine with IC50=8 uM.

Evogliptin hydrochloride
(CAS: 1246960-27-9)

CAS 191282-48-1 C75 trans

C75 trans
(CAS: 191282-48-1)

trans-Tetrahydro-4-methylene-2-octyl-5-oxo-3-furancarboxylic Acid is a well-known fatty acid synthase (FAS) inhibitor. Studies show that trans-Tetrahydro-4-meth...

PD 130908
(CAS: 131505-02-7)

PD 130908 is an effective hypoxic cytotoxin as an analogue of RSU 1069, but less potent than the hypoxic cell radiosensitizer RSU 1069. Toxicity toward hypoxic ...

HI TOPK 032
(CAS: 487020-03-1)

HI TOPK 032 is a novel TOPK inhibitor as a T-LAK-cell-originated protein kinase (TOPK) inhibitor, blocking phosphorylation of the substrate histone H2AX with a...

CAS 6859-01-4 Isorhynchophylline

Isorhynchophylline
(CAS: 6859-01-4)

Rhynchophylline and isorhynchophylline act as noncompetitive antagonists of the NMDA receptor and that this property may contribute to the neuroprotective and a...

CAS 432001-69-9 Skp2 Inhibitor C1

Skp2 Inhibitor C1
(CAS: 432001-69-9)

Skp2 Inhibitor C1(SKPin C1) is a specific small molecule inhibitor of Skp2-mediated p27 degradation, selectively inhibits Skp2-mediated p27 degradation by reduc...

Droxicainide hydrochloride
(CAS: 149572-05-4)

The hydrochloride salt form of Droxicainide, a piperidine derivative, has been found to be an potential antiarrhythmic agent.

CAS 23964-57-0 Articaine hydrochloride

Articaine hydrochloride
(CAS: 23964-57-0)

Articaine is a dental amide-type local anesthetic. It is the most widely used local anesthetic in a number of European countries and is available in many countr...

Nanterinone mesylate
(CAS: 102791-74-2)

Nanterinone mesylate is the methyl sulfonate form of Nanterinone, which is a novel positive inotropic and balanced-type vasodilating drug partially based on pho...

BMS-214662 mesylate
(CAS: 474010-58-7)

BMS-214662 mesylate is a potent and selective inhibitor of farnesyltransferase that induces mitochondrial apoptosis in chronic myeloid leukemia stem/progenitor ...

CAS 17008-69-4 Pseudobufarenogin

Pseudobufarenogin
(CAS: 17008-69-4)

Pseudobufarenogin is a natural compound extracted from toad species with unknown details.

CAS 76901-59-2 Speract

Speract
(CAS: 76901-59-2)

Speract, a peptide associated with eggs of sea urchin, Lytechinus pictus, regulates sperm motility, also stimulates sperm mitochondrial metabolism.

CAS 50-01-1 Guanidine Hydrochloride

Guanidine Hydrochloride
(CAS: 50-01-1)

Guanidine HCl, the crystalline compound of strong alkalinity formed by the oxidation of guanine, is a normal product of protein metabolism and a protein denatur...

CAS 1077-28-7 DL-ThioCtic acid

DL-ThioCtic acid
(CAS: 1077-28-7)

DL-α-Lipoic acid is an non-specific free radical scavenger and has anti-oxidant properties. It could be used as a fat-metabolism stimulator.

CAS 143413-47-2 (Arg)9

(Arg)9
(CAS: 143413-47-2)

(Arg)9, also known as Nona-L-arginine or Peptide R9, is a cell-permeable peptide used for drug delivery with neuroprotective activity (IC50= 0.78 μM in the glut...

Chemical Structure

CAS 131179-95-8 Efaproxiral

Quick Inquiry

Verification code

Featured Items